CN1711996A - 含有双氯芬酸钠和β-环糊精的可注射药物组合物 - Google Patents
含有双氯芬酸钠和β-环糊精的可注射药物组合物 Download PDFInfo
- Publication number
- CN1711996A CN1711996A CNA2005100768303A CN200510076830A CN1711996A CN 1711996 A CN1711996 A CN 1711996A CN A2005100768303 A CNA2005100768303 A CN A2005100768303A CN 200510076830 A CN200510076830 A CN 200510076830A CN 1711996 A CN1711996 A CN 1711996A
- Authority
- CN
- China
- Prior art keywords
- solution
- beta
- diclofenac sodium
- pharmaceutical composition
- diclofenac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 229920000858 Cyclodextrin Polymers 0.000 title abstract description 6
- 239000001116 FEMA 4028 Substances 0.000 title abstract 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title abstract 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 title abstract 2
- 229960004853 betadex Drugs 0.000 title abstract 2
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 title abstract 2
- 229920000136 polysorbate Polymers 0.000 claims abstract description 20
- 229950008882 polysorbate Drugs 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims description 44
- 229960001193 diclofenac sodium Drugs 0.000 claims description 29
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 29
- 229960001259 diclofenac Drugs 0.000 claims description 10
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- -1 polyoxyethylene Polymers 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000007972 injectable composition Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 abstract description 4
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一类可注射药物组合物,含有双氯芬酸钠、β-环糊精和聚山梨醇酯,它们适合用于皮下和肌肉给药。
Description
发明领域
本发明涉及药物组合物领域,特别涉及一种基于双氯芬酸钠的新型可注射药物组合物。
技术现状
双氯芬酸钠,即2-[(2,6-二氯苯基)氨基]苯乙酸单钠盐,具有公认的抗炎活性,并因此很久以来在用于治疗包括外伤引起的和手术后引起的疼痛症状和所有风湿类疾病的各种类型药物制剂中被用作有效成分。
双氯芬酸通过抑制前列素合成而起作用,这是引起炎症和疼痛的主要原因。为了获得最大的疼痛减轻效果,有效成分必须要尽可能地在用药后到达体循环,所以,可注射形式对于治疗肌肉一骨骼系统的急性炎症是特别受欢迎的。
假定双氯芬酸钠是一种微溶于水的化合物,则目前可获得的基于这种有效成分的可注射药物制剂,将含有等于75mg溶解在3ml溶剂中的数量,溶剂由30vol%丙二醇和70vol%水组成。
尽管如此,但是,这种制剂对于病人来说不是令人愉快的,这是因为它令人感觉疼痛;而且,对于给定的单一剂量的总体积来说,用药只有通过肌肉或静脉注射才是可能的。
为了克服因双氯芬酸在水中的低溶解度引起的这些问题,制备了一类组合物,在这类组合物中,双氯芬酸或其盐与环糊精结合。从这类主题的文献已经知道,由于环糊精能与这种有效成分形成一种水溶复合物,所以它们能提高双氯芬酸的溶解性,
但是,还知道即使在羟丙基-β-环糊精帮助下,如果双氯芬酸钠的浓度需要提高,例如,从25mg/ml提高到75mg/ml,则适合于注射的药物组合物,无论如何也不能得到,这是因为会形成双氯芬酸钠的晶体,如欧洲专利第658347B1号中所述。
所以,确定一种具有双氯芬酸钠浓度大于25mg/ml但不存在前述已知药物组合物缺点的可注射制剂的问题,还没有得到解决。
发明概述
本申请人已发现,通过添加非常精确浓度极限的聚山梨醇酯到一种含β-环糊精和浓度大于25mg/ml水的双氯芬酸钠的水溶液中,晶体形成就可得到完全抑制,从而获得在室温和4℃下能够长期保持清澈和稳定的溶液。
因此,本发明目的是一种呈水溶液形式的可注射药物组合物,包括浓度大于25mg/ml水的双氯芬酸钠和β-环糊精,其特征在于它含有至少一种聚山梨醇酯,其数量为所述溶液总体积的0.01~0.06wt%。
本发明药物组合物的特征和优点将在下文中作更详细的描述。
附图简要说明
图1:给出了双氯芬酸钠的血浆浓度相对于时间(在对三个健康志愿者使用实施例1组合物进行肌肉用药(-◆-)和皮下用药(--Δ--)后960分钟)的两个曲线。
发明详细说明
在本发明药物组合物中,优选使用的聚山梨醇酯是聚山梨醇酯20、或聚氧乙烯山梨糖醇单月桂酸酯,可在市场上以商品名Tween20购得。本发明所述组合物中的聚山梨醇酯数量,相对于所述溶液总体积,为0.01~0.06wt%。
本申请人已经发现,如果同样聚山梨醇酯在前述范围之外的浓度进行使用,则无论是在室温还是在4℃,都不能获得令人满意的组合物稳定性结果。
如下文对比例2所述,聚山梨醇酯溶液浓度低于0.01%w/v,则会形成低温时双氯芬酸溶解性不能令人满意的组合物;事实上,在4℃经过一个相对简短贮存后,溶液中就会形成双氯芬酸晶体。从下文给出的对比例3,可以清楚地看出,如果在室温进行贮存,则聚山梨醇酯溶液浓度大于0.06%w/v,会给出相似的溶液稳定性不能令人满意的结果。
根据本发明药物组合物的特别优选实施方式,聚山梨醇酯数量,相对于溶液总体积,等于0.05wt%。
根据本发明优选实施方式,双氯芬酸钠与β-环糊精的摩尔比是在1∶1~1∶1.3范围之间。
β-环糊精优选为羟丙基β-环糊精。
除了有效成分环糊精和聚山梨醇酯之外,本发明药物组合物还可含有药物学可接受的赋形剂,它们选自于那些常用于药物组合物之中用以获得可注射溶液的赋形剂,可注射溶液对于通过肌肉方式或通过皮下方式是可注射的,并可用于治疗疼痛症状。
本发明组合物可以多种配制方法制备得到,特别地按照优选剂量单位75mg双氯芬酸钠制得。
本发明的药物组合物,可通过混合一种聚山梨醇酯水溶液与一种环糊精水溶液和接着添加双氯芬酸钠而制备得到。
已经发现,以前述水溶液形式制得的药物组合物,是长期稳定的,并且在制备后至少三个月没有晶体形成,无论是在室温还是在4℃。
下述的本发明非限制性实施例,是为说明目的而给出的。
实施例1
制备具有0.05%w/v Tween
20的双氯芬酸钠和羟丙基β-环糊精
复合物
制备下述两种溶液:
—溶液A:将1003mg的Tween20溶解在20ml脱离子水中。
—溶液B:在搅拌作用下将6.6g羟丙基β-环糊精溶解在约10ml脱离子水中,直到获得透明无色溶液。
在搅拌作用下,将1.50g的双氯芬酸钠和0.2ml前述制备的溶液A,添加到溶液B中。接着采用脱离子水,使该溶液达到20ml的最终体积,并使之处于搅拌作用之下达约40分钟。
在过滤通过0.22μm过滤器后,得到透明无色溶液,发现其双氯芬酸钠溶液浓度(采用UV分析)为72.91mg/ml。
此溶液按照可注射药物制剂采用的常用方法进行包装和贮存,于室温和4℃条件下,在多于三个月的时间仍保持清澈,没有晶体形成。
实施例2(对比例)
制备具有0.005%w/v Tween
20的双氯芬酸钠和羟丙基β-环糊精
复合物
制备下述两种溶液:
—溶液A:将100.3mg的Tween20溶解在20ml脱离子水中。
—溶液B:在搅拌作用下将6.6g羟丙基β—环糊精溶解在约10ml脱离子水中,直到获得透明无色溶液。
在搅拌作用下,将1.51g的双氯芬酸钠和0.2ml前述制备的溶液A,添加到溶液B中。接着采用脱离子水,使该溶液达到20ml的最终体积,并使之处于搅拌作用之下达约40分钟。接着,溶液过滤通过0.22μm过滤器,得到透明无色溶液,发现其双氯芬酸钠溶液浓度(采用UV分析)为79.14mg/ml。
此溶液按照可注射药物制剂采用的常用方法进行包装和贮存,于室温条件下,在多于三个月的时间仍保持清澈,没有晶体形成,但在4℃条件下,在仅1个月之后,就观察到有呈酸形式和钠盐形式的双氯芬酸晶体形成。
实施例3(对比例)
制备具有0.18%w/v Tween
20的双氯芬酸钠和羟丙基β-环糊精
复合物
在搅拌作用下将17.4g羟丙基β—环糊精溶解在约28ml脱离子水中,直到获得透明无色溶液。在搅拌作用下,将3.75g的双氯芬酸钠和90.1mg的Tween20,添加到其中。
接着采用脱离子水,使该溶液达到50ml的最终体积,并使之处于搅拌作用之下达约40分钟。接着,溶液过滤通过0.22μm过滤器,得到透明无色溶液,发现其双氯芬酸钠溶液浓度(采用UV分析)为80.49mg/ml。
此溶液按照可注射药物制剂采用的常用方法进行包装和贮存。贮存在4℃下的溶液保持清澈,但贮存在室温条件下的相同溶液仅在贮存一周后就观察到混浊。
实施例4
人体的皮下药物动力学
将实施例1所述制备得到的且含有72.91mg/ml的双氯芬酸钠的溶液,于每个含75mg的双氯芬酸钠的小瓶中,在无菌状态下通过消毒过滤法进行消毒。
将该剂量消毒液(75mg)皮下注射到三个健康志愿者的大腿上部,在给药前,从这三个志愿者提取血液样品,在给药后,以一定时间间隔提取血液样品,直到960分钟。
在图1中,给出了血浆双氯芬酸钠水平随时间的变化曲线,由虚线与对应于检测的单个数值的三角形表示。
实施例5
人体的肌肉药物动力学
将实施例1所述制备得到的且含有72.91mg/ml的双氯芬酸钠的溶液,于每个含75mg的双氯芬酸钠的小瓶中,在无菌状态下通过消毒过滤法进行消毒。
将该剂量消毒液(75mg)肌肉注射到三个健康志愿者的大腿上部,在给药前,从这三个志愿者提取血液样品,在给药后,以一定时间间隔提取血液样品,直到960分钟。
在图1中,给出了血浆双氯芬酸水平随时间的变化曲线,由实线与对应于检测的单个数值的菱形表示。
Claims (7)
1、一种呈水溶液形式的可注射药物组合物,含有浓度大于25mg/ml的双氯芬酸钠和β-环糊精,其中,所述组合物还含有至少一种聚山梨醇酯,其数量相对于所述溶液总体积,是在0.01~0.06wt%之间。
2、权利要求1所述药物组合物,其中,所述聚山梨醇酯是聚山梨醇酯20,即,聚氧乙烯山梨糖醇单月桂酸酯。
3、权利要求1所述药物组合物,其中,所述聚山梨醇酯存在的数量,相对于所述溶液总体积,为0.05wt%。
4、权利要求1所述药物组合物,其中,双氯芬酸钠与β-环糊精的摩尔比是在1∶1~1∶1.3范围之间。
5、权利要求1所述药物组合物,其中,所述β-环糊精为羟丙基β-环糊精。
6、权利要求1所述药物组合物,其中,所述双氯芬酸钠浓度是75mg/ml溶液。
7、权利要求1所述药物组合物,呈单位剂量含75mg的双氯芬酸钠的形式。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2004A001245 | 2004-06-22 | ||
IT001245A ITMI20041245A1 (it) | 2004-06-22 | 2004-06-22 | Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1711996A true CN1711996A (zh) | 2005-12-28 |
CN100569230C CN100569230C (zh) | 2009-12-16 |
Family
ID=35033310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100768303A Active CN100569230C (zh) | 2004-06-22 | 2005-06-17 | 含有双氯芬酸钠和β-环糊精的可注射药物组合物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7423028B2 (zh) |
EP (1) | EP1609481B1 (zh) |
JP (1) | JP5113323B2 (zh) |
KR (1) | KR101202649B1 (zh) |
CN (1) | CN100569230C (zh) |
AT (1) | ATE373489T1 (zh) |
CA (1) | CA2510813C (zh) |
DE (1) | DE602005002495T2 (zh) |
DK (1) | DK1609481T3 (zh) |
ES (1) | ES2293482T3 (zh) |
IT (1) | ITMI20041245A1 (zh) |
PL (1) | PL1609481T3 (zh) |
PT (1) | PT1609481E (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432132A (zh) * | 2013-08-31 | 2013-12-11 | 西南大学 | 甲磺酸普立地诺双氯芬酸钠注射液及其制备方法 |
US8809393B2 (en) | 2005-02-01 | 2014-08-19 | Troikaa Pharmaceuticals Ltd | Injectable preparations of diclofenac and its pharmaceutically acceptable salts |
WO2017143877A1 (zh) * | 2016-02-25 | 2017-08-31 | 江苏思邈医药科技有限公司 | 供注射用双氯芬酸钠药物组合物及其制备方法 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007112274A2 (en) * | 2006-03-28 | 2007-10-04 | Javelin Pharmaceuticals, Inc. | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin |
KR20150050595A (ko) | 2006-03-28 | 2015-05-08 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
ITMI20121205A1 (it) | 2012-07-11 | 2014-01-12 | Glycores 2000 Srl | Composizione con attivita' antinfiammatoria ed analgesica da somministrare per uso esterno mediante vaporizzazione |
US20140275261A1 (en) | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
KR20180098625A (ko) * | 2015-12-30 | 2018-09-04 | 제넨테크, 인크. | 분해가 감소된 폴리소르베이트를 갖는 제형 |
EP3216443A1 (en) | 2016-03-10 | 2017-09-13 | Athenion AG | Beverage preparation capsule for delivery of a solubilisate |
IT201600075246A1 (it) | 2016-07-19 | 2018-01-19 | Jointherapeutics S R L | Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi. |
US11110073B2 (en) | 2017-03-24 | 2021-09-07 | Cadila Healthcare Limited | Storage stable aqueous injectable solution comprising diclofenac |
EP3388054A1 (en) | 2017-04-12 | 2018-10-17 | Athenion AG | Dispensing cap containing a solubilisate of a pharmaceutically active agent or dietary supplement |
US20220280463A1 (en) | 2019-09-09 | 2022-09-08 | Ftf Pharma Private Limited | Pharmaceutical formulations comprising diclofenac |
US11707443B2 (en) | 2019-09-26 | 2023-07-25 | Rk Pharma Inc. | Storage stable aqueous parenteral solutions comprising diclofenac |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA949182B (en) * | 1993-12-02 | 1995-07-26 | South African Druggists Ltd | Pharmaceutical composition |
US5554650A (en) * | 1994-07-28 | 1996-09-10 | Southern Research Institute | Antiphlogistic, analgesic, antipyretic injection preparation |
CA2284000C (en) * | 1997-03-12 | 2012-01-03 | Abbott Laboratories | Hydrophilic binary systems for the administration of cyclosporine |
US6365180B1 (en) * | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US20020016359A1 (en) * | 2000-06-29 | 2002-02-07 | Hellberg Mark R. | Compositions and methods of treating neurodegenerative diseases |
US7008934B2 (en) * | 2001-06-28 | 2006-03-07 | Baxter International Inc. | Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins |
-
2004
- 2004-06-22 IT IT001245A patent/ITMI20041245A1/it unknown
-
2005
- 2005-06-15 JP JP2005174529A patent/JP5113323B2/ja active Active
- 2005-06-17 CN CNB2005100768303A patent/CN100569230C/zh active Active
- 2005-06-20 KR KR1020050053096A patent/KR101202649B1/ko active IP Right Grant
- 2005-06-21 AT AT05105474T patent/ATE373489T1/de active
- 2005-06-21 CA CA2510813A patent/CA2510813C/en active Active
- 2005-06-21 PT PT05105474T patent/PT1609481E/pt unknown
- 2005-06-21 DE DE602005002495T patent/DE602005002495T2/de active Active
- 2005-06-21 DK DK05105474T patent/DK1609481T3/da active
- 2005-06-21 EP EP05105474A patent/EP1609481B1/en active Active
- 2005-06-21 PL PL05105474T patent/PL1609481T3/pl unknown
- 2005-06-21 ES ES05105474T patent/ES2293482T3/es active Active
- 2005-06-21 US US11/158,517 patent/US7423028B2/en active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8809393B2 (en) | 2005-02-01 | 2014-08-19 | Troikaa Pharmaceuticals Ltd | Injectable preparations of diclofenac and its pharmaceutically acceptable salts |
CN103432132A (zh) * | 2013-08-31 | 2013-12-11 | 西南大学 | 甲磺酸普立地诺双氯芬酸钠注射液及其制备方法 |
CN103432132B (zh) * | 2013-08-31 | 2015-01-21 | 西南大学 | 甲磺酸普立地诺双氯芬酸钠注射液及其制备方法 |
WO2017143877A1 (zh) * | 2016-02-25 | 2017-08-31 | 江苏思邈医药科技有限公司 | 供注射用双氯芬酸钠药物组合物及其制备方法 |
CN107126418A (zh) * | 2016-02-25 | 2017-09-05 | 江苏思邈医药科技有限公司 | 供注射用双氯芬酸钠药物组合物及其制备方法 |
CN107126418B (zh) * | 2016-02-25 | 2020-05-29 | 江苏思邈医药科技有限公司 | 供注射用双氯芬酸钠药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR101202649B1 (ko) | 2012-11-19 |
EP1609481A1 (en) | 2005-12-28 |
DK1609481T3 (da) | 2008-01-07 |
KR20060049413A (ko) | 2006-05-18 |
DE602005002495D1 (de) | 2007-10-31 |
US7423028B2 (en) | 2008-09-09 |
PT1609481E (pt) | 2007-12-31 |
CN100569230C (zh) | 2009-12-16 |
CA2510813C (en) | 2013-02-12 |
US20050282776A1 (en) | 2005-12-22 |
PL1609481T3 (pl) | 2008-02-29 |
ITMI20041245A1 (it) | 2004-09-22 |
JP5113323B2 (ja) | 2013-01-09 |
JP2006008684A (ja) | 2006-01-12 |
EP1609481B1 (en) | 2007-09-19 |
ATE373489T1 (de) | 2007-10-15 |
ES2293482T3 (es) | 2008-03-16 |
CA2510813A1 (en) | 2005-12-22 |
DE602005002495T2 (de) | 2008-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1711996A (zh) | 含有双氯芬酸钠和β-环糊精的可注射药物组合物 | |
CN1041793C (zh) | 氟化氯霉素药物组合物 | |
DE69834956T2 (de) | Stabile Insulinformulierungen | |
JP5683810B2 (ja) | メトトレキセート濃厚溶液 | |
CN1273187C (zh) | 稳定性提高的无锌或低锌胰岛素制剂 | |
AU2009223649B2 (en) | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection | |
CN1767815A (zh) | 非水单相载体和使用这类载体的制剂 | |
EP2307056B1 (en) | Stabilized aqueous formulation containing paracetamol | |
CN1368891A (zh) | 莫西沙星/氯化钠制剂 | |
CN105431145B (zh) | 用于呋塞米的皮下施用的药物制剂 | |
CN1373665A (zh) | 左西孟旦的药物溶液 | |
CN101095942A (zh) | 一种包含稳定剂的Exendin注射剂药物配方 | |
KR20100112632A (ko) | 수용성인 프로포폴 전구약물의 약제학적 수성 제제 | |
US11744899B2 (en) | Pharmaceutical composition containing a hyaluronic acid derivative | |
JP5070670B2 (ja) | N−[o−(p−ピバロイルオキシベンゼンスルホニルアミノ)ベンゾイル]グリシン・モノナトリウム塩・4水和物の凍結乾燥製剤およびその製造方法 | |
US4289783A (en) | Etomidate-containing compositions | |
DE60022759T2 (de) | Erythropoietin formulierungen des mehrfachdosis-typs | |
EP2076243A1 (de) | Flüssigformulierung von g-csf | |
AU2004263036B2 (en) | Glycyrrhizin high-concentration preparation | |
KR20200018438A (ko) | 향상된 용해도의 약물-함유 제형 | |
US20050233968A1 (en) | Polyamino acid-based insulin preparation | |
EP3407875A1 (en) | Aqueous pharmaceutical formulation comprising propofol | |
CN1895253A (zh) | 一个新的盐酸洛美沙星滴眼液及其制备方法 | |
CN1334725A (zh) | 普鲁泊福(2,6-二异丙基苯酚)和2,5-二-氧-甲基-1,4;3,6-双脱水-d-葡萄糖醇作为溶剂的胃肠外的溶液 | |
WO2006096079A2 (en) | Pharmaceutical composition comprising a biosynthetic analog of human insulin, and its use in the treatment of diabetes mellitus. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060217 Address after: Lugano Switzerland 6903 Applicant after: Altgon AG Address before: Swiss Manzano 13-CH-6903 Applicant before: IBSA Inst Biochimique SA |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |